Associations between ERBB2 amplification and progression-free survival and overall survival in advanced stage, suboptimally-resected epithelial ovarian cancers: A Gynecologic Oncology Group study

Gynecologic Oncology

Volumn 113, Issue 3, 2009, Pages 341-347

  Farley, John ^a   Fuchiuji, Sartoru ^b   Darcy, Kathleen M ^c   Tian, Chunqiao ^c   Hoskins, William J ^d   McGuire, William P ^e   Hanjani, Parviz ^f   Warshal, David ^g   Greer, Benjamin E ^h   Belinson, Jerome ⁱ   Birrer, Michael J ^b  

^a UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c Buffalo Niagara Enterprise   (United States)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^e Harry and Jeanette Weinberg Cancer Institute   (United States)

^f ABINGTON MEMORIAL HOSPITAL   (United States)

^g Department of Anesthesiology   (United States)

^h UNIVERSITY OF WASHINGTON   (United States)

ⁱ LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Carcinogenesis; ERBB2; FISH; Gene amplification; Ovary

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PACLITAXEL;

ADULT; ADVANCED CANCER; ARTICLE; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; GENE AMPLIFICATION; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; OVARY CANCER; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS, PHASE II AS TOPIC; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; GENE AMPLIFICATION; GENES, ERBB-2; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MIDDLE AGED; OVARIAN NEOPLASMS; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; YOUNG ADULT;

EID: 67349095676     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2009.02.009     Document Type: Article

References (39)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2008. CA Cancer J. Clin. 58 (2008) 71-96
2. Young R. Cancer of the ovary. 4th ed. (1993), Lippincott, Philadelphia, Pa 1126-1163
3. Afify A.M., Werness B., and Mark H.F. Her2 oncogene amplification in stage I and stage III ovarian papillary serous carcinoma. Exp. Mol. Pathol. 66 (1999) 163-169
4. Young S.R., Liu W.H., Brock J.A., and Smith S.T. ERBB2 and chromosome 17 centromere studies of ovarian cancer by fluorescence in situ hybridization. Genes Chromosomes Cancer 16 (1996) 130-137
5. Berchuck A., Kamel A., Whitaker R., et al. Overexpression of Her2 is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res. 50 (1990) 4087-4091
6. Kacinski B.M., Mayer A.G., King B.L., Carter D., and Chambers S.K. NEU protein overexpression in benign, borderline, and malignant ovarian neoplasms. Gynecol. Oncol. 44 (1992) 245-253
7. Rubin S.C., Finstad C.L., Federici M.G., Scheiner L., Lloyd K.O., and Hoskins W.J. Prevalence and significance of Her2 expression in early epithelial ovarian cancer. Cancer 73 (1994) 1456-1459
8. Rubin S.C., Finstad C.L., Wong G.Y., Almadrones L., Plante M., and Lloyd K.O. Prognostic significance of Her-2 expression in advanced epithelial ovarian cancer: a multivariate analysis. Am. J. Obstet. Gynecol. 168 (1993) 162-169
9. Slamon D.J., Godolphin W., Jones L.A., et al. Studies of the Her2 proto-oncogene in human breast and ovarian cancer. Science 244 (1989) 707-712
10. Bookman M.A., Darcy K.M., Clarke-Pearson D., Boothby R.A., Horowitz I.R., and Campos S.M. Evaluation of monoclonal humanized anti-HER2 antibody (Trastuzumab) in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group. Women's Oncol. Rev. 3 (2003) 239-240
11. Serrano-Olvera A., Duenas-Gonzalez A., Gallardo-Rincon D., Candelaria M., and De la Garza-Salazar J. Prognostic, predictive and therapeutic implications of HER2 in invasive epithelial ovarian cancer. Cancer Treat. Rev. 32 (2006) 180-190
12. Mano M.S., Awada A., Di Leo A., et al. Rates of topoisomerase II-alpha and HER-2 gene amplification and expression in epithelial ovarian carcinoma. Gynecol. Oncol. 92 (2004) 887-895
13. Wu Y., Soslow R.A., Marshall D.S., Leitao M., and Chen B. Her-2 expression and amplification in early stage ovarian surface epithelial neoplasms. Gynecol. Oncol. 95 (2004) 570-575
14. Mayr D., Kanitz V., Amann G., et al. Her-2 gene amplification in ovarian tumours: a comprehensive immunohistochemical and FISH analysis on tissue microarrays. Histopathology 48 (2006) 149-156
15. Lee C.H., Huntsman D.G., Cheang M.C., et al. Assessment of Her-1, Her-2, And Her-3 expression and Her-2 amplification in advanced stage ovarian carcinoma. Int. J. Gynecol. Pathol. 24 (2005) 147-152
16. McGuire W.P., Hoskins W.J., Brady M.F., et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N. Engl. J. Med. 334 (1996) 1-6
17. Darcy KM, Brady WE, McBroom JW, et al. Associations between p53 overexpression and multiple measures of clinical outcome in high-risk, early stage or suboptimally-resected, advanced stage epithelial ovarian cancers: a Gynecologic Oncology Group study. Gynecol Oncol (GYN-08-446R1).
18. 2 from contingency tables, and the calculation of p. J. R. Stat. Soc. 85 1 (1992) 87-94
19. Mehta C.R., and Patel N.R. A network algorithm for performing Fisher's exact test in r × c contingency tables. J. Am. Stat. Assoc. 78 (1983) 427-434
20. Kaplan E.L., and Meier P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc. 53 (1958) 457-481
21. Savage I.R. Contributions to the theory of rank order statistics - the two sample case. Ann. Math. Stat. 27 (1956) 590-615
22. Cox D.R. Regression models and life tables. J. Royal Stat. Soc. 34 (1972) 187-220
23. Hosmer D.W., and Lemeshow S. Applied Survival Analysis: Regression Modeling of Time to Event Data (1999), John Wiley&Sons, Inc, New York, NY
24. Camp R.L., Dolled-Filhart M., King B.L., and Rimm D.L. Quantitative analysis of breast cancer tissue microarrays shows that both high and normal levels of HER2 expression are associated with poor outcome. Cancer Res. 63 (2003) 1445-1448
25. Cherchi P.L., Marras V., Capobianco G., et al. Prognostic value of p53, c-erb-B2 and MIB-1 in endometrial carcinoma. Eur. J. Gynaecol. Oncol. 22 (2001) 451-453
26. Heffner H.M., Freedman A.N., Asirwatham J.E., and Lele S.B. Prognostic significance of p53, PCNA, and c-erbB-2 in endometrial endocarcinoma. Eur. J. Gynaecol. Oncol. 20 (1999) 8-12
27. Hetzel D.J., Wilson T.O., Keeney G.L., Roche P.C., Cha S.S., and Podratz K.C. Her-2 expression: a major prognostic factor in endometrial cancer. Gynecol. Oncol. 47 (1992) 179-185
28. Nathanson D.R., Culliford A.T., Shia J., et al. HER 2/neu expression and gene amplification in colon cancer. Int. J. Cancer 105 (2003) 796-802
29. Tsutsui S., Ohno S., Murakami S., Kataoka A., Kinoshita J., and Hachitanda Y. Prognostic value of the combination of epidermal growth factor receptor and c-erbB-2 in breast cancer. Surgery 133 (2003) 219-221
30. Zhang F., Yang Y., Smith T., et al. Correlation between HER-2 expression and response to neoadjuvant chemotherapy with 5-fluorouracil, doxorubicin, and cyclophosphamide in patients with breast carcinoma. Cancer 97 (2003) 1758-1765
31. Saffari B., Jones L.A., el-Naggar A., Felix J.C., George J., and Press M.F. Amplification and overexpression of Her-2 (c-erbB2) in endometrial cancers: correlation with overall survival. Cancer Res. 55 (1995) 5693-5698
32. Rolitsky C.D., Theil K.S., McGaughy V.R., Copeland L.J., and Niemann T.H. Her-2 amplification and overexpression in endometrial carcinoma. Int. J. Gynecol. Pathol. 18 (1999) 138-143
33. Schmidt M., Lewark B., Kohlschmidt N., et al. Long-term prognostic significance of Her-2 in untreated node-negative breast cancer depends on the method of testing. Breast Cancer Res. 7 (2005) R256-R266
34. Meden H., Marx D., Roegglen T., Schauer A., and Kuhn W. Overexpression of the oncogene c-erbB-2 (HER2/neu) and response to chemotherapy in patients with ovarian cancer. Int. J. Gynecol. Pathol. 17 (1998) 61-65
35. Katsaros D., Theillet C., Zola P., et al. Concurrent abnormal expression of erbB-2, myc and ras genes is associated with poor outcome of ovarian cancer patients. Anticancer Res. 15 (1995) 1501-1510
36. Fukushi Y., Sato S., Yokoyama Y., Kudo K., Maruyama H., and Saito Y. Detection of numerical aberration in chromosome 17 and c-erbB2 gene amplification in epithelial ovarian cancer using recently established dual color FISH. Eur. J. Gynaecol. Oncol. 22 (2001) 23-25
37. Wang Z.R., Liu W., Smith S.T., Parrish R.S., and Young S.R. c-myc and chromosome 8 centromere studies of ovarian cancer by interphase FISH. Exp. Mol. Pathol. 66 (1999) 140-148
38. Muggia F.M., Braly P.S., Brady M.F., et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study. J. Clin. Oncol. 18 1 (2000) 106-115
39. Wolff A.C., Hammond M.E., Schwartz J.N., et al. American society of clinical oncology, college of american pathologists. american society of clinical oncology/college of American pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J. Clin. Oncol. 25 1 (2007) 118-145